Cytovance Biologics and Selexys Pharmaceutical have entered an agreement for the execution of a biopharmaceutical development and manufacturing collaboration for Anti-PSGL-1, a monoclonal antibody (mAb) being developed for treatment of inflammation associated with Crohn’s disease.

Cytovance will lead the cell culture process optimization, recovery and purification development, as well as provide cGMP manufacturing, technical and regulatory support for Selexys’ clinical program. “Our development and manufacturing collaboration extends our strategic partnership with Cytovance as they have demonstrated on time execution of our first antibody for sickle cell disease. We look forward to this continued alliance as we work together towards advancing this important therapy to patients who suffer from Crohn’s,” said Scott Rollins, president and chief executive officer, Selexys.

“We are pleased that Selexys has once again chosen Cytovance to work in concert as their development and manufacturing partner,” said Darren Head, president and chief executive officer of Cytovance Biologics. “This agreement confirms our shared commitment to highlight the biotechnology life science sector in Oklahoma City and is a testament to our clients to provide unsurpassed quality and innovative technical experience to their most important assets.”